CONMED Corporation to Announce Third Quarter 2025 Financial Results on November 5, 2025
CONMED Corporation (
NYSE: CNMD) today announced that it will report financial results for the third quarter 2025 after the market close on Wednesday, November 5, 2025. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.
3 Stocks Under $50 with Open QuestionsStocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market LandscapeSeptember 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (
NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Masimo, Integra LifeSciences, CONMED, IQVIA, and Charles River Laboratories Shares Are Soaring, What You Need To KnowA number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
1 Healthcare Stock with Exciting Potential and 2 We QuestionFrom novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 18.6% gain.
Solventum, CONMED, and STERIS Shares Are Falling, What You Need To KnowA number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
3 Small-Cap Stocks That Concern UsInvestors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
1 Cash-Producing Stock to Consider Right Now and 2 That UnderwhelmA company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
CONMED Corporation Adds Kim Kelderman to its Board of Directors
CONMED Corporation (
NYSE: CNMD) today announced that Kim Kelderman will be joining its Board of Directors effective September 8, 2025.
1 Profitable Stock for Long-Term Investors and 2 We Brush OffWhile profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To KnowA number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
CNMD Q2 Deep Dive: Product Growth and Supply Chain Progress Offset Margin PressureMedical tech company CONMED (
NYSE:CNMD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 3.1% year on year to $342.3 million. The company expects the full year’s revenue to be around $1.37 billion, close to analysts’ estimates. Its non-GAAP profit of $1.15 per share was 2.4% above analysts’ consensus estimates.
Thermo Fisher, ICU Medical, CONMED, Pediatrix Medical Group, and IQVIA Stocks Trade Up, What You Need To KnowA number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
CONMED Corporation Announces Quarterly Cash Dividend
CONMED Corporation (
NYSE: CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025.
3 Value Stocks We Keep Off Our RadarValue stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
CONMED’s (NYSE:CNMD) Q2 Sales Top EstimatesMedical tech company CONMED (
NYSE:CNMD) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 3.1% year on year to $342.3 million. The company expects the full year’s revenue to be around $1.37 billion, close to analysts’ estimates. Its non-GAAP profit of $1.15 per share was 2.4% above analysts’ consensus estimates.
CONMED Corporation Announces Second Quarter 2025 Financial Results
CONMED Corporation (
NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2025.
CONMED (CNMD) Q2 Earnings: What To ExpectMedical tech company CONMED (
NYSE:CNMD)
will be announcing earnings results this Wednesday after market close. Here’s what to look for.
Titan International, Richardson Electronics, RTX, Hilton Grand Vacations, and CONMED Shares Skyrocket, What You Need To KnowA number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally.
Enovis, CONMED, Astrana Health, Privia Health, and Waters Corporation Stocks Trade Down, What You Need To KnowA number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
1 Small-Cap Stock Worth Investigating and 2 We Find RiskyInvestors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To KnowA number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
1 Healthcare Stock with Competitive Advantages and 2 to Be Wary OfHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 6%. This performance is a far cry from the S&P 500’s 7.5% ascent.
